Navigation Links
Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Date:5/13/2009

sting treatments."

About Circassia

Circassia is a specialty biopharmaceutical company focused on the field of allergy. The company's range of allergy therapeutics utilizes its proprietary T-cell epitope desensitization technology, ToleroMune. Circassia's products offer potential major clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year. ToleroMune technology has additional potential regulatory and supply benefits for Circassia. Its state-of-the-art manufacturing fits with changes in the European regulatory environment, where authorities are increasingly treating allergen immunotherapies as pharmaceutical products, and eliminating the batch-to-batch potency variability that is an intrinsic feature of many currrent treatments. Circassia has a highly experienced management team with a proven track record in product development and commercialization. Having successfully completed two fundraising rounds the company is backed by a syndicate of world-class venture capital and institutional investors, including Imperial Innovations, Lansdowne Partners, Goldman Sachs and Invesco Perpetual.

    For more information please visithttp://www.circassia.co.uk.

    Contacts:
    Steve Harris
    Rob Budge
    CEO RJB Communications
    Circassia
    Tel: +44(0)1865-760969
    Tel: +44(0)1865-784574


'/>"/>
SOURCE Circassia Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
2. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
3. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
4. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
5. Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
6. Boston Scientific Begins Clinical Trial Enrollment for New Everolimus-Eluting Stent
7. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
8. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
9. AFFiRiS Begins Development of a Parkinsons Vaccine
10. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
11. Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015 Qiming Venture ... to Managing Partner effective immediately. William ... has lead and participated in many Qiming healthcare deals, ... in the Chinese market. Qiming, s success in healthcare ... he has distinguished himself with his outstanding advocacy and ...
(Date:7/1/2015)... 1, 2015 ExeGi Pharma, a company focused ... announced today that it has been granted a product ... Products Directorate (NNHPD) to sell Visbiome™ in ... by Professor Claudio De Simone , MD, PhD ... Professor De Simone recently signed an exclusive agreement with ...
(Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
Breaking Medicine Technology:Qiming Announces the Promotion of William Hu to Managing Partner 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 2ExeGi Pharma Secures Canadian Approval For Well Studied Probiotic 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... ... natural forms, such as organically raised chickens and eggs. Eating organic foods and ... chickens is cleaner and more environmentally friendly than production chicken farming. Choosing home ...
(Date:7/1/2015)... ... July 01, 2015 , ... ... cancer enterprise of Hospital Corporation of America (HCA), as it further expands its ... announced today. , With this new partnership, OncLive’s editorial and marketing teams ...
(Date:7/1/2015)... ... - (PRWEB) July 01, 2015 , ... Lisa Keys, the widow of U.S. ... 15-16th (MSG Keys’ birthday) in memory of her late husband and all of America’s ... of the Bronze Star Medal, died during a Special Forces training exercise in December ...
(Date:7/1/2015)... ... July 01, 2015 , ... RowdMap Inc. is a proud ... paper: “Pro-actively Identifying the High-Cost Patient Population: Insights from the Health Care Transformation ... http://www.hcttf.org/resouces-tools . , The Healthcare Transformation Task Force is a group of ...
(Date:7/1/2015)... ... July 01, 2015 , ... A Priority ... published a top ten list they hope will guide future mesothelioma research. Surviving ... read it now. , More than 450 mesothelioma patients, caregivers, and ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Offer New Chicken Coop Designs 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 2Health News:OncLive® Welcomes Sarah Cannon Cancer Network to Its Strategic Alliance Partnership Program 3Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 2Health News:Wife of Fallen Special Forces Soldier to Host Nationwide ‘Virtual 5K’ for Charity 3Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 2Health News:A Population Based Approach to Pay for Value: RowdMap, Inc. Contributes to Health Care Transformation Task Force White Paper 3Health News:New Report Identifies Top 10 Mesothelioma Research Priorities, According to Surviving Mesothelioma 2
... mental health workers gauge patient,s state of mind, researchers ... widely used psychological test has the potential to gauge ... more insight into what their patients are thinking, a ... used to show whether people automatically associate things with ...
... ... pharmaceutical ingredients into silicones in a safe and controlled environment , ... Carpinteria, CA (Vocus) ... and manufacturer of silicone compounds for the healthcare and pharmaceutical industries, announces the ...
... Cell Research Center scientists are exploring the mysteries of human ... repairing damaged organs, and drug development. Center staff also offer ... cells. The center was established with a grant to Professors ... Jersey through its Commission on Science and Technology. The ...
... ... Medical Records , ... 14, 2010 -- WebLOQ, Inc ., a leader in privacy solutions for secure and ... Medical Audit Resource Service, Inc. (MARSI) to ensure the security of its ...
... Long hours and strict cigarette policies may explain the ... stress may actually lower smokers, nicotine dependence, finds a ... boost levels of smoking. , German researchers used an ... the smoking habits of 197 employed participants in the ...
... ... ... Md. (Vocus) April 14, 2010 -- PMSI , one of the nation’s largest ... , the nation’s leader in pain medication monitoring solutions, today announced a strategic partnership ...
Cached Medicine News:Health News:Test May Measure Suicidal Tendencies 2Health News:NuSil Technology Announces Completion of Clean Room Facilities 2Health News:Rutgers' Stem Cell Research Center derives new cell lines and trains stem cell scientists 2Health News:WebLOQ Selected By MARSI to Streamline Medical Audit Reviews From Dispersed Healthcare Community 2Health News:WebLOQ Selected By MARSI to Streamline Medical Audit Reviews From Dispersed Healthcare Community 3Health News:WebLOQ Selected By MARSI to Streamline Medical Audit Reviews From Dispersed Healthcare Community 4Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 2Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 3
Our soft guedel airway is clear and has a color coded bite block. Airway has a smooth finish and is Latex Free. Recommended for single use. Non-Sterile....
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
Medicine Products: